Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Therapeutic Advances in Cardiovascular Disease is Scopus-indexed (Q2, CiteScore 4.6), WoS ESCI, DOAJ. Published by SAGE Publications Ltd.
Checked against the index lists dated .
ISSN 1753-9447Verify ISSN ↗1753-9455Verify ISSN ↗
Publisher: SAGE Publications Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cardiology and Cardiovascular Medicine | 120 / 409 | 70th | Q2 |
| Pharmacology (medical) | 114 / 278 | 59th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2007–present, best quartile Q2, CiteScore 4.6.
Therapeutic Advances in Cardiovascular Disease is Q2 in Cardiology and Cardiovascular Medicine (rank 120 of 409) and Q2 in Pharmacology (medical) (rank 114 of 278), by CiteScore 2025.
Therapeutic Advances in Cardiovascular Disease is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.6, which places it in quartile Q2 at the 70th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.862, quartile Q2, with an H-index of 44.
The publisher lists an article processing charge of about US$2,650 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Therapeutic Advances in Cardiovascular Disease is published by SAGE Publications Ltd. Its print ISSN is 1753-9447 and its online ISSN is 1753-9455.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Therapeutic Advances in Cardiovascular Disease has an h-index of 49 and a 2-year mean of 4.19 citations per paper (OpenAlex). Its Scopus CiteScore is 4.6, quartile Q2. On 2-year citations it ranks #37 of 398 Scopus journals in Cardiology and Cardiovascular Medicine.
Therapeutic Advances in Cardiovascular Disease published 14 papers in 2025; its busiest recent year was 2018 with 31. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2021–2026), authors are most often from United States (20%), United Kingdom (8.6%) and China (8.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (3.7 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.